The current state of introduction of human papillomavirus vaccination into national immunization schedules in Europe: First results of the VENICE2 2010 survey

Eurosurveillance

Volumn 15, Issue 47, 2010, Pages

  Dorleans, F ^a   Giambi, C ^b   Dematte, L ^c   Cotter, S ^d   Stefanoff, P ^e   Mereckiene, J ^d   O'flanagan, D ^d   Lopalco, P ^f   D'ancona, F ^b   Levy Bruhl D ^a  

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CINECA   (Italy)

^d HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^e NATIONAL MEDICINES INSTITUTE   (Poland)

^f EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AGE DISTRIBUTION; ARTICLE; COST; DECISION SUPPORT SYSTEM; EUROPE; FINANCIAL MANAGEMENT; GEOGRAPHIC DISTRIBUTION; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; HEALTH CENTER; HEALTH PROGRAM; HEALTH SERVICE; HEALTH SURVEY; HUMAN; INSURANCE; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTION; POLICY; PUBLIC-PRIVATE PARTNERSHIP; SEX RATIO; VACCINE EUROPEAN NEW INTEGRATED COLLABORATION EFFORT 2; WART VIRUS;

EID: 78649803667     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. D'Ancona F, on behalf of VENICE II group. VENICE II: Go on combining our efforts towards a European common vaccination policy. Euro Surveill. 2009;14(12):pii=19161. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19161
2. Pastore Celentano L, Lopalco PL, O'Flanagan D, Lévy-Bruhl D, Ferro A, Tridente G, et al. VENICE: Europe's new network for vaccination. Euro Surveill. 2007;12(3):pii=3116. Available from: http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId=3116
3. King LA, Lévy-Bruhl D, O'Flanagan D, Bacci S, Lopalco PL, Kudjawu Y, et al. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey. Euro Surveill. 2008;13(33):pii=18954. Available from: http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=18954
4. Lévy-Bruhl D, Bousquet V, King LA, O'Flanagan D, Bacci S, Lopalco PL, et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe. Results of the VENICE 2008 survey. Eur J Cancer. 2009;45(15):2709-27013.
5. De Kok I, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst. 2009;101(15):1083-1092.
6. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirusvaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27(37):5133-5141.
7. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010;28(24):4091-4102.
8. La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, Ricciardi W. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. Vaccine. 2010;28(19):3379-3384.
9. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010;26(2):183-191.